Striverdi Respimat FDA Approval History
FDA Approved: Yes (First approved July 31, 2014)
Brand name: Striverdi Respimat
Generic name: olodaterol
Dosage form: Inhalation Spray
Company: Boehringer Ingelheim Pharmaceuticals Inc.
Treatment for: COPD
Striverdi Respimat (olodaterol) is a once-daily, long-acting beta-agonist (LABA) for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
Development timeline for Striverdi Respimat
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.